| Trial ID: | L3597 |
| Source ID: | NCT02765204
|
| Associated Drug: |
Dapagliflozin
|
| Title: |
A Single-dose Cross-over Study to Assess Direct and Indirect Effects of Dapagliflozin on Pancreatic Alpha and Beta Cells in Patients With Type 2 Diabetes
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: Dapagliflozin|DRUG: Saxagliptin|DRUG: Glucose
|
| Outcome Measures: |
Primary: Change in plasma glucagon levels from baseline to 0.5 hour after single-dose administration of drug., Washout period of 2-6 weeks between the interventions, At start and 0.5 hour after the start of each intervention|Change in plasma glucagon levels from baseline to 1 hour after single-dose administration of drug., At start and 1 hour after the start of each intervention|Change in plasma glucagon levels from baseline to 2 hours after single-dose administration of drug., At start and 2 hours after the start of each intervention|Change in plasma glucagon levels from baseline to 3 hours after single-dose administration of drug., At start and 3 hours after the start of each intervention|Change in plasma glucagon levels from baseline to 5 hours after single-dose administration of drug., At start and 5 hours after the start of each intervention|Change in plasma glucagon levels from baseline to 5.5 hours after single-dose administration of drug., At start and 5.5 hours after the start of each intervention|Change in plasma glucagon levels from baseline to 6 hours after single-dose administration of drug., At start and 6 hours after the start of each intervention|Change in plasma glucagon levels from baseline to 7 hours after single-dose administration of drug., At start and 7 hours after the start of each intervention |
|
| Sponsor/Collaborators: |
Sponsor: Uppsala University | Collaborators: AstraZeneca
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
15
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2016-03
|
| Completion Date: |
2016-12
|
| Results First Posted: |
|
| Last Update Posted: |
2016-12-12
|
| Locations: |
Dept of Medical Sciences Uppsala University Hospital, Uppsala, 75185, Sweden
|
| URL: |
https://clinicaltrials.gov/show/NCT02765204
|
